NASDAQ$HAIN
Hain Celestial · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Hain Celestial's Q3 2024 financial results were reported, highlighting gross margin expansion and strong operating cash flow driven by the Hain Reimagined strategy.
Hain Celestial reported a decrease in net sales by 3.7% to $438.4 million, but showcased progress in gross margin expansion with a 60-basis point increase. The company reduced its debt leverage to 3.9x and generated strong operating cash flow, reflecting strategic actions to simplify the business and strengthen the balance sheet.
- Net sales decreased by 3.7% year-over-year to $438.4 million, with a similar decrease in organic net sales.
- Gross profit margin increased by 60 basis points to 22.1%, and adjusted gross profit margin increased by 90 basis points to 22.3%.
- Net loss was $48.2 million, an improvement from a net loss of $115.7 million in the prior year period.
- Adjusted EBITDA increased by 17.5% year-over-year to $43.8 million, with an adjusted EBITDA margin of 10.0%.
Headline financials
Revenue & EPS history
Hain Celestial · Revenue · Quarterly
$438M
Revenue by segment
Hain Celestial · $425M total across 2 segments · Q1 2024
- North America$260M-9.8%61.2%
- International$165M+9.3%38.8%
Forward guidance
Hain Celestial is revising its fiscal year 2024 guidance due to underperformance in infant formula recovery, snacks execution, and personal care stabilization. Organic net sales are expected to decline 3 to 4% year-over-year, and adjusted EBITDA is projected to be between $150 million and $155 million. Free cash flow guidance is reaffirmed at $40 million to $45 million.
Tailwinds
- Aggressively addressing Personal Care stabilization through portfolio and operating footprint consolidation.
- Working closely with formula supplier to ensure a full recovery beginning in the second half of 2024.
- Realigned the commercial business in North America with a series of leadership changes.
- Clear plan to accelerate our execution in the North America region.
- Free cash flow guidance is reaffirmed and expected to be $40 million to $45 million.
Headwinds
- Infant formula business did not recover as expected as our supplier did not meet their commitment.
- Execution in our Snacks business did not meet our standards.
- Stabilization of our Personal Care business is taking longer than expected.
- Organic net sales are expected to decline 3 to 4% year-over-year.
- Adjusted EBITDA is expected to be between $150 million and $155 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-1.5%
Avg return
Earnings day
-1.9%
Avg return
5 days after
-2.3%
Avg return
30 days after
46%
31 / 67 earnings
Positive
+20.9%
Q4 2024
Best reaction
-48.4%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +12.9% | +17.4% | -3.7% | |
| Q2 2026 | -19.5% | -22.0% | -48.0% | |
| Q1 2026 | +14.4% | +32.7% | -3.7% | |
| Q3 2025 | -48.4% | -36.1% | -36.1% | |
| Q2 2025 | -10.7% | -13.6% | -11.3% | |
| Q1 2025 | -16.7% | -24.9% | -7.1% | |
| Q4 2024 | +20.9% | +17.1% | +20.9% | |
| Q3 2024 | +5.6% | +14.1% | +13.4% | |
| Q2 2024 | -11.9% | -12.7% | -17.4% | |
| Q1 2024 | -6.0% | -3.6% | -6.7% | |
| Q4 2023 | -2.5% | -9.1% | -16.4% | |
| Q3 2023 | -14.4% | -19.8% | -31.0% | |
| Q2 2023 | -10.0% | -12.8% | -19.6% | |
| Q1 2023 | +1.4% | +10.6% | -8.1% | |
| Q4 2022 | -13.9% | -17.0% | -31.1% | |
| Q3 2022 | -24.9% | -20.7% | -22.6% | |
| Q2 2022 | +1.4% | +2.1% | -5.9% | |
| Q1 2022 | +5.0% | -9.0% | -14.9% | |
| Q4 2021 | -9.7% | -6.5% | +0.1% | |
| Q3 2021 | +0.0% | -0.9% | +0.2% | |
| Q2 2021 | +4.5% | +6.2% | +7.3% | |
| Q1 2021 | +2.1% | +11.9% | +13.8% | |
| Q4 2020 | -4.4% | -7.5% | -4.3% | |
| Q3 2020 | +10.9% | +16.7% | +11.3% | |
| Q2 2020 | +9.3% | +7.6% | -6.2% | |
| Q1 2020 | +7.0% | +5.7% | +3.9% | |
| Q4 2019 | +3.8% | +4.4% | +17.3% | |
| Q3 2019 | -3.7% | +0.6% | -11.5% | |
| Q2 2019 | -10.6% | +1.5% | +20.9% | |
| Q1 2019 | -14.9% | -15.5% | -26.1% | |
| Q4 2018 | -3.6% | -0.2% | -7.5% | |
| Q3 2018 | -2.2% | -2.5% | -3.4% | |
| Q2 2018 | -5.5% | -8.7% | -2.3% | |
| Q1 2018 | +1.6% | +3.8% | +19.0% | |
| Q4 2017 | -2.4% | -2.6% | +0.2% | |
| Q3 2017 | -4.7% | +4.8% | +32.0% | |
| Q1 2017 | -4.7% | +4.8% | +32.0% | |
| Q2 2017 | -4.7% | +4.8% | +32.0% | |
| Q4 2016 | -4.7% | +4.8% | +32.0% | |
| Q3 2016 | +9.0% | — | — | |
| Q2 2016 | -4.2% | — | — | |
| Q1 2016 | -4.8% | — | — | |
| Q4 2015 | -6.2% | — | — | |
| Q3 2015 | -0.5% | — | — | |
| Q2 2015 | +6.2% | — | — | |
| Q1 2015 | +1.0% | — | — | |
| Q4 2014 | +10.2% | — | — | |
| Q3 2014 | +8.0% | — | — | |
| Q2 2014 | -4.5% | — | — | |
| Q1 2014 | +3.8% | — | — | |
| Q4 2013 | +9.5% | — | — | |
| Q3 2013 | -1.8% | — | — | |
| Q2 2013 | +1.0% | — | — | |
| Q1 2013 | -1.0% | — | — | |
| Q4 2012 | +19.4% | — | — | |
| Q3 2012 | -0.6% | — | — | |
| Q2 2012 | +1.5% | — | — | |
| Q1 2012 | -1.3% | — | — | |
| Q4 2009 | +1.0% | — | — | |
| Q4 2011 | +1.0% | — | — | |
| Q3 2011 | +1.5% | — | — | |
| Q3 2010 | +1.5% | — | — | |
| Q2 2011 | +1.6% | — | — | |
| Q2 2010 | +1.6% | — | — | |
| Q4 2010 | -0.8% | — | — | |
| Q1 2010 | -0.8% | — | — | |
| Q1 2011 | -0.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro